DB:RV7

Stock Analysis Report

Executive Summary

Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally.

Snowflake

Exceptional growth potential with excellent balance sheet.


Similar Companies

Share Price & News

How has Halozyme Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RV7 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

5.6%

RV7

5.5%

DE Biotechs

-0.3%

DE Market


1 Year Return

21.6%

RV7

-1.9%

DE Biotechs

10.9%

DE Market

Return vs Industry: RV7 exceeded the German Biotechs industry which returned -1.9% over the past year.

Return vs Market: RV7 exceeded the German Market which returned 10.9% over the past year.


Shareholder returns

RV7IndustryMarket
7 Day5.6%5.5%-0.3%
30 Day25.7%-0.8%2.6%
90 Day15.8%-4.8%11.8%
1 Year21.6%21.6%-1.6%-1.9%14.4%10.9%
3 Year45.3%45.3%65.5%63.4%24.1%13.2%
5 Year146.1%146.1%7.2%4.8%33.0%14.8%

Price Volatility Vs. Market

How volatile is Halozyme Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Halozyme Therapeutics undervalued compared to its fair value and its price relative to the market?

9.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: RV7 (€17.1) is trading below our estimate of fair value (€18.98)

Significantly Below Fair Value: RV7 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: RV7 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: RV7 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RV7's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RV7 is overvalued based on its PB Ratio (11.4x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Halozyme Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

63.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RV7 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: RV7 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RV7's is expected to become profitable in the next 3 years.

Revenue vs Market: RV7's revenue (22.6% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: RV7's revenue (22.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RV7's Return on Equity is forecast to be very high in 3 years time (119.9%).


Next Steps

Past Performance

How has Halozyme Therapeutics performed over the past 5 years?

17.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RV7 has a high level of non-cash earnings.

Growing Profit Margin: RV7 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RV7 is unprofitable, but has reduced losses over the past 5 years at a rate of 17.7% per year.

Accelerating Growth: Unable to compare RV7's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RV7 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: RV7 has a negative Return on Equity (-16.29%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Halozyme Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: RV7's short term assets ($342.0M) exceeds its short term liabilities ($108.0M)

Long Term Liabilities: RV7's short term assets ($342.0M) exceeds its long term liabilities (17.0M)


Debt to Equity History and Analysis

Debt Level: RV7's debt to equity ratio (26%) is considered satisfactory.

Reducing Debt: RV7's debt to equity ratio has reduced from 116.5% to 26% over the past 5 years.


Balance Sheet

Inventory Level: RV7 has a low level of unsold assets or inventory.

Debt Coverage by Assets: RV7's debt is covered by short term assets (assets are 5.4x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RV7 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RV7 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Halozyme Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate RV7's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RV7's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RV7's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RV7's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RV7's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Halozyme Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.4yrs

Average management tenure


CEO

Helen Torley (56yo)

5.8yrs

Tenure

US$5,799,669

Compensation

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. Prior to joining Halozyme in January 2014, she served as the  ...


CEO Compensation Analysis

Compensation vs Market: Helen's total compensation ($USD5.80M) is above average for companies of similar size in the German market ($USD2.73M).

Compensation vs Earnings: Helen's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.4yrs

Average Tenure

56yo

Average Age

Experienced Management: RV7's management team is considered experienced (3.4 years average tenure).


Board Age and Tenure

10.5yrs

Average Tenure

60yo

Average Age

Experienced Board: RV7's board of directors are seasoned and experienced ( 10.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$50,458,23105 Nov 19
Third Security, LLC
EntityCompany
Shares3,497,856
Max PriceUS$14.43
SellUS$19,96606 Aug 19
Dimitrios Chondros
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer & Senior VP
Shares1,328
Max PriceUS$15.04
SellUS$23,128,85703 Jul 19
Randal Kirk
EntityIndividual
Shares1,567,633
Max PriceUS$14.75
SellUS$27,043,26507 Jun 19
Randal Kirk
EntityIndividual
Shares1,980,897
Max PriceUS$13.65
SellUS$36,24321 Feb 19
Dimitrios Chondros
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer & Senior VP
Shares2,536
Max PriceUS$14.29

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Harry Leonhardt (62yo)

    Senior VP

    • Tenure: 4.6yrs
    • Compensation: US$1.91m
  • William Fallon (62yo)

    Senior VP &

    • Tenure: 1.7yrs
    • Compensation: US$708.80k
  • Helen Torley (56yo)

    President

    • Tenure: 5.8yrs
    • Compensation: US$5.80m
  • Al Kildani

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 1yrs
  • Mike Paolucci (59yo)

    Chief Human Resources Officer & VP

    • Tenure: 4.3yrs
  • Laurie Stelzer (51yo)

    Senior VP & CFO

    • Tenure: 4.4yrs
    • Compensation: US$1.95m
  • Homa Yeganegi

    Senior VP & Global PEGPH20 Program Lead

    • Tenure: 1.7yrs
  • Dimitrios Chondros (54yo)

    Chief Medical Officer & Senior VP

    • Tenure: 2.5yrs
    • Compensation: US$1.94m
  • Benjamin Hickey (44yo)

    Senior VP & Chief Commercial Officer

    • Tenure: 1.2yrs
    • Compensation: US$3.83m
  • Ed Gemo

    VP, Chief Information & Security Officer

    • Tenure: 4.8yrs

Board Members

  • Connie Matsui (65yo)

    Independent Chairperson of the Board

    • Tenure: 0yrs
    • Compensation: US$305.01k
  • Jeff Henderson (54yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$290.01k
  • Dan Von Hoff (71yo)

    Member of the Scientific Advisory Board

    • Tenure: 15.3yrs
  • Jeffrey Bleil (66yo)

    Member of the Advisory Board

    • Tenure: 0yrs
  • Greg Frost (47yo)

    Chairman of Scientific Advisory Board

    • Tenure: 5.8yrs
    • Compensation: US$68.17k
  • Gerhard Baumgartner

    Member of Scientific Advisory Board

    • Tenure: 15.4yrs
  • Ken Kelley (60yo)

    Independent Director

    • Tenure: 15.5yrs
    • Compensation: US$275.01k
  • Sue Bailey (75yo)

    Member of Scientific Advisory Board

    • Tenure: 14.3yrs
  • Matt Posard (52yo)

    Independent Director

    • Tenure: 6.7yrs
    • Compensation: US$270.01k
  • Helen Torley (56yo)

    President

    • Tenure: 5.8yrs
    • Compensation: US$5.80m

Company Information

Halozyme Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Halozyme Therapeutics, Inc.
  • Ticker: RV7
  • Exchange: DB
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.790b
  • Listing Market Cap: US$2.521b
  • Shares outstanding: 146.14m
  • Website: https://www.halozyme.com

Number of Employees


Location

  • Halozyme Therapeutics, Inc.
  • 11388 Sorrento Valley Road
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HALONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 2003
RV7DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2003
0J2OLSE (London Stock Exchange)YesCommon StockGBUSDJan 2003

Biography

Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzy ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/21 20:34
End of Day Share Price2019/11/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.